The Valley Desk

NCT01200589 · Interventional trial

Single Agent Ofatumumab Vs. Single Agent Rituximab in Indolent B-Cell Non Hodgkin Lymphoma Relapsed After Rituximab-Containing Therapy

Overall registry status Terminated

Phase 3

Conditions Non-Hodgkin's Lymphoma

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov